Expert Access - Running Immunosuppressants by LC/MS/MS

Eileen Burd

James C. Ritchie, PhD, DABCC, FACB

Tuesday, August 16, 2011
1:00-2:00 pm Eastern (U.S.) time



Running Immunosuppressants by LC/MS/MS

The 2004 discontinuation of support for a popular immunosuppressant test platform highlights the critical need to ensure continuity of TDM to support a transplant program. In the vast majority of cases, clinicians can’t wait for results from a regional reference lab. Testing frequency must be discussed with clinical staff to ensure adequate availability of TDM results. Mass spectrometry testing is a viable alternative to immunoassay platforms for analysis of immunosuppressant concentrations in transplant patients.


Dr. Ritchie received a BS in Zoology in 1970 and a Masters in Public Health Epidemiology in 1976, both from the University of Michigan. He also earned a PhD in Pharmacology from Duke University in 1995. He has been continuously involved in clinical laboratory work since 1972. Currently, Dr. Ritchie is Co-director of the Emory University Core, Special Chemistry, and Immunology Laboratories. He is also a co-director of the Emory ComACC post doctoral training program.

Dr. Ritchie has been a member of AACC and the TDM Division since 1984. Nationally, he has served on the Continuing Education committee, the Publications committee, and was a founding member of the Proteomics division, serving as treasurer and chairman of the Division. He has also served locally as the chairman and secretary/treasurer of AACC’s Southeast Section. Currently he is secretary of the NACB board of directors and a member of the ABCC board.

His specific areas of research interest are therapeutic drug monitoring and the neuropharmacology of mental illness, including the pharmacology of antidepressants, antipsychotics, and antiepileptics during pregnancy.

Page Access: